AR035400A1 - Un compuesto antagonista del receptor de adenosina a1, una composicion farmaceutica que lo comprende y un proceso para prepararlo - Google Patents
Un compuesto antagonista del receptor de adenosina a1, una composicion farmaceutica que lo comprende y un proceso para prepararloInfo
- Publication number
- AR035400A1 AR035400A1 ARP010105594A ARP010105594A AR035400A1 AR 035400 A1 AR035400 A1 AR 035400A1 AR P010105594 A ARP010105594 A AR P010105594A AR P010105594 A ARP010105594 A AR P010105594A AR 035400 A1 AR035400 A1 AR 035400A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- group
- alkyl
- alkylsulfonyl
- amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 title 1
- 229960005305 adenosine Drugs 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- -1 acilaminoalquilamino Chemical group 0.000 abstract 13
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 10
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 125000000304 alkynyl group Chemical group 0.000 abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 4
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 4
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 229910019142 PO4 Inorganic materials 0.000 abstract 2
- 125000004442 acylamino group Chemical group 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 125000006323 alkenyl amino group Chemical group 0.000 abstract 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 abstract 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 abstract 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 2
- 125000004664 haloalkylsulfonylamino group Chemical group 0.000 abstract 2
- 125000005419 heteroarylsulfonylamino group Chemical group 0.000 abstract 2
- 125000005646 oximino group Chemical group 0.000 abstract 2
- 125000006170 pentacyclic group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 2
- 239000010452 phosphate Substances 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 125000006168 tricyclic group Chemical group 0.000 abstract 2
- 229940124258 Adenosine A1 receptor antagonist Drugs 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229910004727 OSO3H Inorganic materials 0.000 abstract 1
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 239000002598 adenosine A1 receptor antagonist Substances 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 239000011574 phosphorus Substances 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe un compuesto antagonista del receptor de adenosina A1, caracterizado por la fórmula (1): en donde R1 y R2 son seleccionados independientemente del grupo formado por: a) hidrógeno, b) alquilo, alquenilo o alquinilo, en donde dicho alquilo, alquenilo o alquinilo es o no sustituido o funcionalizado con uno o más sustituyentes seleccionados del grupo formado por hidroxi, alcoxi, amino, alquilamino, dialquilamino, heterociclilo, acilamino, alquilsulfonilamino y heterociclilcarbonilamino; y c) arilo o arilo sustituido; R3 es seleccionado del grupo formado por: (a) un grupo bicíclico, tricíclico o pentacíclico seleccionado del grupo formado por el grupo de fórmulas (2) en donde el grupo bicíclico, tricíclico o pentacíclico es o no sustituido o funcionalizado con uno o más sustituyentes seleccionados del grupo formado por: (i) alquilo, alquenilo y alquinilo, en donde cada grupo alquilo, alquenilo o alquinilo es o no sustituido o funcionalizado con uno o más sustituyentes seleccionados del grupo formado por (alcoxicarbonil)aralquilcarbamoilo, (amino)(R5)acihidrazinilcarbonilo, (amino)(R5)aciloxicarboxi, (hidroxi)(carboalcoxi)alquilcarbamoilo, acilaminoalquilamino, aciloxi, aldehido, alquenoxi, alquenilamino, alquenilsulfonilamino, alcoxi, alcoxicarbonilo, alcoxicarbonilalquilamino, alcoxicarbonilamino, alcoxicarbonilaminoaciloxi, alcoxicarbonilaminoalquilamino, alquilamino, alquilaminoalquilamino, alquilcarbamoilo, alquilfosfono, alquilsulfonilamino, alquilsulfoniloxi, amino, aminoaciloxi, aminoalquilaralquilcarbamoilo, aminoalquilcarbamoilo, aminoalquilheterocicloalquilcarbamoilo, aminocicloalquilalquilcicloalquilcarbamoilo, aminocicloalquilcarbamoilo, aralcoxicarbonilo, aralcoxicarbonilamino, arilheterociclo, ariloxi, arilsulfonilamino, arilsulfoniloxi, carbamoilo, carbonilo, ciano, cianoalquilcarbamoilo, cicloalquilamino, dialquilamino, dialquilaminoalquilamino, dialquilaminoalquilcarbamoilo, dialquilfosfono, haloalquilsulfonilamino, halógeno, heterociclilo, heterociclilalquilamino, heterociclilcarbamoilo, hidroxi, hidroxialquilsulfonilamino, oximino, fosfato, fosfono, -R5 R5-alcoxi, R5-alquil(alquil)amino, R5-alquilalquilcarbamoilo, R5-alquilamino, R5-alquilcarbamoilo, R5-alquilsulfonilo, R5-alquilsulfonilamino, R5-alquiltio, R5-heterociclilcarbonilo, aralquilamino sustituido, arilcarboxialcoxicarbonilo sustituido, arilsulfonilaminoalquilamino sustituido, heteroarilsulfonilamino sustituido, heterociclo sustituido, heterociclilaminoalquilamino sustituido, heterociclilsulfonilamino sustituido, sulfoxiacilamino, tiocarbamoilo, trifluorometilo; y (ii) (alcoxicarbonil)aralquilcarbamoilo, (amino)(R5)acilhidrazinilcarbonilo, (amino)(R5)aciloxicarboxi, (hidroxi)(carboalcoxi)alquilcarbamoilo, acilaminoalquilamino, aciloxi, aldehído, alquenoxi, alquenilamino, alquenilsulfonilamino, alcoxi, alcoxicarbonilo, alcoxicarbonilalquilamino, alcoxicarbonilamino, alcoxicarbonilaminoaciloxi, alcoxicarbonilaminoalquilamino, alquilamino, alquilaminoalquilamino, alquilcarbamoilo, alquilfosfono, alquilsufonilamino, alquilsulfoniloxi, amino, aminoaciloxi, aminoalquilaralquilcarbamoilo, aminoalquilcarbamoilo, aminoalquilheterociclilalquilcarbamoilo, aminocicloalquilalquilcicloalquilcarbamoilo, aminocicloalquilcarbamoilo, aralcoxicarbonilo, aralcoxicarbonilamino, arilheterociclilo, ariloxi, arilsulfonilamino, arilsulfoniloxi, carbamoilo, carbonilo, ciano, cianoalquilcarbamoilo, cicloalquilamino, dialquilamino, dialquilaminoalquilamino, dialquilaminoalquilcarbamoilo, dialquilfosfono, haloalquilsulfonilamino, halógeno, heterociclilo, heterociclilalquilamino, heterociclilcarbamoilo, hidroxi, hidroxialquilsulfonilamino, oximino, fosfato, fósforo, -R5 R5-alcoxi, R5-alquil(alquil)amino, R5-alquilalquilcarbamoilo, R5-alquilamino, R5-alquilcarbamoilo, R5-alquilsulfonilo, R5-alquilsulfonilamino, R5-alquiltio, R5-heterociclilcarbonilo, aralquilamino sustituido, arilcarboxialcoxicarbonilo sustituido, arilsulfonilaminoalquilamino sustituido, heteroarilsulfonilamino sustituido, heterociclo sustituido, heterociclilaminoalquilamino sustituido, sulfoxiacilamino, tiocarbamoilo, trifluorometilo; R4 es seleccionado del grupo formado por hidrógeno, alquilo C1-4, (alquilo C1-4)-CO2H y fenilo, en donde los grupos alquilo C1-4, (alquilo C1-4)-CO2H y fenilo son o no sustituidos o funcionalizados con uno a tres sustituyentes seleccionados del grupo formado por halógeno, -OH, OMe,-NH2-NO2 bencilo y bencilo funcionalizado con uno a tres sustituyentes seleccionados del grupo formado por halógeno, -OH, OMe, -NH2 y -NO2, R5 es seleccionado del grupo formado por -(CR1R2)nCOOH, -C(CF3)2OH, -CONHNHSO2CF3, -CONHOR4, -CONHSO2R4, -CONHSO2NHR4, -C(OH)R4PO3H2, -NHCOCF3, -NHCONHSO2R4, -NHPO3H2, NHSO2R4, -NHSO2NHCOR4, -OPO3H2, -OSO3H, -PO(OH)R4, -PO3H2, -SO3H, -SO2NHR4, -SO3NHCOR4, -SO3NHCONHCO2R4 y los siguientes grupo de fórmulas (3); n= 0, 1, 2, o 3; A es seleccionado de grupo formado por -CH=CH, -(CH)m-(CH)m, CH=CH-CH2 y -CH2-CH=CH; m = 1 o 2; X es O o S; Z es seleccionado del grupo formado por una ligadura simple, -O-, (CH2)n-, -O(CH2)1-2-, CH2OCH2-, -(CH2)1-2O-, y R6 es seleccionado del grupo formado por hidrógeno, alquilo, acilo, alquilsulfonilo, aralquilo, aralquilo sustituido, alquilo sustituido, y heterociclilo; y R7 es seleccionado del grupo formado por: a) hidrógeno; b) alquilo, alquenilo con no menos de 3 carbonos, o alquinilo con no menos de 3 carbonos, en donde dicho alquilo, alquenilo o alquinilo es o no sustituido o funcionalizado con uno o más sustituyentes seleccionados del grupo formado por hidroxi, alcoxi, amino, alquilamino, dialquilamino, heterociclilo, acilamino, alquilsulfonilamino y heterociclilcarbonilamino; c) arilo o arilo sustituido; y d) alquilarilo o arilo sustituido con alquilo. La invención provee además una composición farmacéutica que incluye el compuesto antedicho y un proceso para prepararlo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25065800P | 2000-12-01 | 2000-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035400A1 true AR035400A1 (es) | 2004-05-26 |
Family
ID=22948640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105594A AR035400A1 (es) | 2000-12-01 | 2001-11-30 | Un compuesto antagonista del receptor de adenosina a1, una composicion farmaceutica que lo comprende y un proceso para prepararlo |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US6605601B2 (es) |
| EP (1) | EP1347981B1 (es) |
| JP (2) | JP2004514723A (es) |
| KR (1) | KR20040011439A (es) |
| CN (1) | CN100497340C (es) |
| AR (1) | AR035400A1 (es) |
| AT (1) | ATE394402T1 (es) |
| AU (2) | AU2002219977B2 (es) |
| BG (1) | BG107849A (es) |
| BR (1) | BR0115833A (es) |
| CA (1) | CA2430508C (es) |
| CZ (1) | CZ20031513A3 (es) |
| DE (1) | DE60133931D1 (es) |
| EA (1) | EA009814B1 (es) |
| EE (1) | EE200300260A (es) |
| ES (1) | ES2305139T3 (es) |
| GE (1) | GEP20094697B (es) |
| HU (1) | HUP0400530A3 (es) |
| IL (1) | IL156046A0 (es) |
| IS (1) | IS6821A (es) |
| MX (1) | MXPA03004857A (es) |
| MY (1) | MY127120A (es) |
| NO (1) | NO20032483L (es) |
| NZ (1) | NZ526511A (es) |
| PL (1) | PL362642A1 (es) |
| SK (1) | SK6552003A3 (es) |
| TR (1) | TR200300766T2 (es) |
| TW (1) | TWI293301B (es) |
| UA (1) | UA75625C2 (es) |
| WO (1) | WO2002044182A1 (es) |
| YU (1) | YU42903A (es) |
| ZA (2) | ZA200304067B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2238335T3 (es) * | 1999-12-24 | 2005-09-01 | Kyowa Hakko Kogyo Co., Ltd. | Derivados de purina condensados. |
| CZ20031513A3 (cs) * | 2000-12-01 | 2003-09-17 | Biogen, Inc. | Kondenzované purinové deriváty jako antagonisty A1 adenosinového receptoru |
| WO2004074247A2 (en) * | 2003-02-19 | 2004-09-02 | Endacea, Inc. | A1 adenosine receptor antagonists |
| US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
| RU2367442C2 (ru) * | 2003-04-25 | 2009-09-20 | Новокардия, Инк. | Способ нормализации мочеиспускания при нарушении функции почек |
| US20060252780A1 (en) * | 2003-04-25 | 2006-11-09 | Kyowa Hakko Kogyo Co., Ltd. | Fused pyrimidine derivatives |
| CA2528385C (en) * | 2003-06-06 | 2011-03-15 | Endacea, Inc. | A1 adenosine receptor antogonists |
| CA2601032A1 (en) * | 2005-03-11 | 2006-09-21 | Aderis Pharmaceuticals, Inc. | Substituted 9-alkyladenines and the use thereof |
| US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
| AU2007235372A1 (en) * | 2006-04-06 | 2007-10-18 | Novacardia, Inc. | Co-administration of adenosine A1 receptor antagonists and anticonvulsants |
| MX2008014672A (es) | 2006-05-19 | 2009-03-09 | Abbott Lab | Derivados de alcano azabiciclico sustituidos con bicicloheterociclo fusionado activos en el sistema nervioso central. |
| JP2009540003A (ja) * | 2006-06-16 | 2009-11-19 | ノヴァカーディア，インク． | Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善 |
| WO2007150026A2 (en) | 2006-06-23 | 2007-12-27 | Incyte Corporation | Purinone derivatives as hm74a agonists |
| JP5584466B2 (ja) | 2006-06-23 | 2014-09-03 | インサイト コーポレイション | ＨＭ７４ａ受容体アゴニストとしてのプリノン誘導体 |
| US20090197900A1 (en) * | 2007-03-29 | 2009-08-06 | Howard Dittrich | Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist |
| WO2008121882A1 (en) * | 2007-03-29 | 2008-10-09 | Novacardia, Inc. | Improved methods of administration of adenosine a1 receptor antagonists |
| WO2011063268A2 (en) * | 2009-11-19 | 2011-05-26 | Biogen Idec Ma Inc | Novel synthetic methods |
| US20130109645A1 (en) | 2010-03-31 | 2013-05-02 | The united States of America,as represented by Secretary,Dept.,of Health and Human Services | Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders |
| SG11202006435XA (en) | 2018-01-04 | 2020-08-28 | Impetis Biosciences Ltd | Tricyclic compounds, compositions and medicinal applications thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06102662B2 (ja) | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | キサンチン誘導体 |
| ES2152207T3 (es) * | 1989-10-20 | 2001-02-01 | Kyowa Hakko Kogyo Kk | Derivados condensados de la purina. |
| ATE178060T1 (de) | 1991-09-23 | 1999-04-15 | Univ Florida State | Darstellung von substituierten isoserinestern unter verwendung von metallalkoxiden und s- lactamen |
| EP0884318A4 (en) * | 1996-10-07 | 2002-10-23 | Kyowa Hakko Kogyo Kk | CONDENSED PURINE DERIVATIVES |
| JP2002505687A (ja) * | 1997-06-18 | 2002-02-19 | ディスカバリー セラピューティクス，インコーポレイテッド | 脈管再生手順の後の再狭窄を防止するための組成物および方法 |
| US6489331B1 (en) * | 1998-07-02 | 2002-12-03 | Kyowa Hakko Kogyo Co., Ltd. | Remedies for diabetes |
| ES2238335T3 (es) * | 1999-12-24 | 2005-09-01 | Kyowa Hakko Kogyo Co., Ltd. | Derivados de purina condensados. |
| CZ20031513A3 (cs) * | 2000-12-01 | 2003-09-17 | Biogen, Inc. | Kondenzované purinové deriváty jako antagonisty A1 adenosinového receptoru |
-
2001
- 2001-11-30 CZ CZ20031513A patent/CZ20031513A3/cs unknown
- 2001-11-30 EA EA200300629A patent/EA009814B1/ru not_active IP Right Cessation
- 2001-11-30 JP JP2002546552A patent/JP2004514723A/ja active Pending
- 2001-11-30 BR BR0115833-3A patent/BR0115833A/pt not_active Application Discontinuation
- 2001-11-30 MY MYPI20015481A patent/MY127120A/en unknown
- 2001-11-30 AR ARP010105594A patent/AR035400A1/es unknown
- 2001-11-30 EE EEP200300260A patent/EE200300260A/xx unknown
- 2001-11-30 AU AU2002219977A patent/AU2002219977B2/en not_active Ceased
- 2001-11-30 TR TR2003/00766T patent/TR200300766T2/xx unknown
- 2001-11-30 AU AU1997702A patent/AU1997702A/xx active Pending
- 2001-11-30 PL PL01362642A patent/PL362642A1/xx not_active Application Discontinuation
- 2001-11-30 EP EP01998550A patent/EP1347981B1/en not_active Expired - Lifetime
- 2001-11-30 DE DE60133931T patent/DE60133931D1/de not_active Expired - Lifetime
- 2001-11-30 MX MXPA03004857A patent/MXPA03004857A/es active IP Right Grant
- 2001-11-30 CA CA2430508A patent/CA2430508C/en not_active Expired - Fee Related
- 2001-11-30 NZ NZ526511A patent/NZ526511A/en unknown
- 2001-11-30 AT AT01998550T patent/ATE394402T1/de not_active IP Right Cessation
- 2001-11-30 IL IL15604601A patent/IL156046A0/xx unknown
- 2001-11-30 CN CNB018208711A patent/CN100497340C/zh not_active Expired - Fee Related
- 2001-11-30 UA UA2003066041A patent/UA75625C2/uk unknown
- 2001-11-30 YU YU42903A patent/YU42903A/sh unknown
- 2001-11-30 HU HU0400530A patent/HUP0400530A3/hu unknown
- 2001-11-30 KR KR10-2003-7007322A patent/KR20040011439A/ko not_active Abandoned
- 2001-11-30 ES ES01998550T patent/ES2305139T3/es not_active Expired - Lifetime
- 2001-11-30 SK SK655-2003A patent/SK6552003A3/sk not_active Application Discontinuation
- 2001-11-30 WO PCT/US2001/044991 patent/WO2002044182A1/en not_active Ceased
- 2001-11-30 TW TW090129678A patent/TWI293301B/zh active
- 2001-11-30 US US09/997,740 patent/US6605601B2/en not_active Expired - Fee Related
- 2001-11-30 GE GEAP20017016A patent/GEP20094697B/en unknown
-
2003
- 2003-05-20 IS IS6821A patent/IS6821A/is unknown
- 2003-05-26 ZA ZA200304067A patent/ZA200304067B/en unknown
- 2003-05-27 BG BG107849A patent/BG107849A/bg unknown
- 2003-05-27 US US10/446,573 patent/US7022686B2/en not_active Expired - Fee Related
- 2003-06-02 NO NO20032483A patent/NO20032483L/no not_active Application Discontinuation
-
2004
- 2004-10-28 ZA ZA200408755A patent/ZA200408755B/xx unknown
-
2009
- 2009-12-07 JP JP2009278047A patent/JP2010053148A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035400A1 (es) | Un compuesto antagonista del receptor de adenosina a1, una composicion farmaceutica que lo comprende y un proceso para prepararlo | |
| IL256375A (en) | New histological histories, process for their preparation and pharmaceutical preparations containing them | |
| TW200618804A (en) | Phosphonate analogs of HIV inhibitor compounds | |
| AR044402A1 (es) | Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. | |
| RU2018102365A (ru) | Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их | |
| RU2014151850A (ru) | Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их | |
| PE20200837A1 (es) | Compuestos macrociclicos derivados de diazaciclononadeca [1,2,3-c/d] indenos inhibidores de la proteina de diferenciacion celular de leucemia mieloide inducida (mcl-1) y composiciones farmaceuticas que los comprenden | |
| WO2009093209A3 (ru) | 2-AЛKИЛAMИHO-3-APИЛCУЛЬФOHИЛ-ЦИKЛOAЛKAHO [e ИЛИ d] ПИPAЗOЛO [1,5-a] ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| NI201000198A (es) | Compuestos triazina como inhibidores mtor y quinasa p13. | |
| RU2013130250A (ru) | Замещенные пуриновые и 7-деазапуриновые соединения | |
| EA201390022A1 (ru) | Конденсированные гетероциклические соединения в качестве ингибиторов фосфодиэстераз (фдэ) | |
| DE602004003506D1 (de) | Perfluorpolyetheramidgebundene phosphonate, phosphate und derivate davon | |
| BRPI0409680A (pt) | análogos de fosfonato anti-cáncer | |
| AR062011A1 (es) | Derivados de diazol y sus composiciones como inhibidores de itpkb | |
| KR880006241A (ko) | 9-사이클로펜틸- 치환된 아데닌 유도체 | |
| PE20230251A1 (es) | Terapia de combinacion que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| AR067869A1 (es) | Derivados de piridina y pirimidina | |
| SG178902A1 (en) | (thio)morpholine derivatives as s1p modulators | |
| DE602004005960D1 (de) | Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten | |
| NO20004295D0 (no) | Nye pyridinforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem | |
| AR040724A1 (es) | Compuesto de imidazopiridina, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento | |
| DE602004027409D1 (de) | Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation | |
| AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
| AR045447A1 (es) | Compuestos triciclicos inhibidores de transferasa de proteina de farnesilo novedosos como agentes antitumorales | |
| PE20080534A1 (es) | Compuestos derivados de piridinas y piridazinas sustituidos como inhibidores de kdr |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |